Published in final edited form as:

Tetrahedron Lett. 2016 December 14; 57(50): 5658–5660. doi:10.1016/j.tetlet.2016.11.012.

Multigram-scale Synthesis of Enantiopure 3,3-Difluoroproline

Christelle Doebelin, Yuanjun He, and Theodore M. Kamenecka*

Department of Molecular Therapeutics, The Scripps Research Institute, Scripps Florida, 130 Scripps Way #A2A, Jupiter, FL 33458, USA

Abstract

An efficient route for the synthesis of enantiopure 3,3-difluoroproline on multigram-scale is described herein. The deoxofluorination can be achieved with DAST on the corresponding racemic pyrrolidinone in good yield. Resolution of the racemate by crystallization with D- and L-tyrosine hydrazide provides both enantiomers of 3,3-difluoroproline in high yield and ee%.

Graphical abstract

To create your abstract, type over the instructions in the template box below.

Fonts or abstract dimensions should not be changed or altered.

Keywords

3,3-difluoroproline; Chiral resolution; Gram-scale synthesis

For 60 years, the replacement of hydrogen by fluorine has been used in medicinal chemistry to modulate properties of druglike compounds.^{1–5} A fluorine atom is regarded as a bioisostere of hydrogen. The substitution of a hydrogen atom by fluorine can block undesirable metabolism at a specific site, can increase lipophilicity and/or binding affinity and can modulate ADME parameters. Countless drugs and clinical candidates take advantage of fluorine atoms for these reasons. More recently, fluorinated amino acids have been incorporated in proteins to study stability, configuration, protein folding, and protein-protein interactions.^{6–9} Optically pure 4,4-difluoroproline was synthesized over 30 years

* Corresponding author. kameneck@scripps.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary data

Supplementary data (experimental protocols and spectroscopic data) associated with this article can be found in the online version.

ago. It has shown is usefulness especially in medicinal chemistry to significantly improve potency, selectivity and/or solubility.^{10–13} We were in need of enantiomerically pure 3,3-difluoroproline in gram quantities, and were surprised by the lack of suitable methods to synthesize it. Hence, we devised a synthetic route that could deliver optically pure material in just a few steps with minimal purifications. Herein we describe our approach.

Two major synthetic pathways have been described for the synthesis of 3,3-difluoroproline derivatives. In 1993, Hart and Coward, described the synthesis of racemic 3,3-difluoroproline from the masked 3-hydroxyprolinol **3** (Scheme 1).¹⁴ Compound **3** can be obtained in five steps following the procedure describe by Tamaru et al.¹⁵ In 1995, Shi et al. reported a synthetic pathway providing racemic β,β -difluoroproline starting from β,β -difluoro- α -keto-esters.¹⁶

This process was then optimized to allow the synthesis of chiral β,β -difluoroproline derivatives (Scheme 2).¹⁷ The number of steps in these routes and the use of specific reagents (ie. allyltributyltin/AIBN, ozone) make these synthetic pathways time-consuming and difficult to scale up. We envisioned an alternate strategy to 3,3-difluoroproline starting from a commercially available β -ketoproline derivative that was both fast and scalable. For larger scale synthesis (> 30 g), we synthesized the β -ketoproline and adjusted the protecting groups to suit our needs.

We initiated our synthetic investigations from commercially available ethyl N-Boc-3-oxopyrrolidine-2-carboxylate **19**. The key step is the deoxofluorination of the β -oxo group.¹⁸ Literature data as well as our own in-house studies confirm that the use of nucleophilic fluorination agents like DAST and its relatives on acyclic 3-keto esters fails to provide the desired 3,3-difluoro ester.

These reactions lead to the formation of difluoro olefin esters and the occurrence of several side products.¹⁹ To our knowledge, the fluorination of an α -amino β -keto esters had only been described in the patent literature.^{20–22} With this in mind, we tested three different fluorination agents (Deoxo-Fluor^{®23}, DAST²⁴ and XtalFluor-E^{®25}) with ketone **19** in CH₂Cl₂ (Scheme 3). In all reactions conditions tested, desired product **20** was detected, however despite using six equivalents of fluorination agent, the reactions failed to go to conversion. The reaction was ultimately improved by using 3 equivalents of DAST *without* solvent. Under these reaction conditions, 80% conversion of ketone **19** was observed by ¹H-NMR. The 3,3-difluoro ester **20** was isolated in 64% yield on multigram scale (5–6 g) starting with ketone **19**. Surprisingly, the reaction was quite clean, affording none of the by-products observed when using acyclic β -ketoesters. The hydrolysis of the Boc protecting group and the ester was achieved in a single step using aqueous 6N HCl at 60°C for 5h. We observed significant degradation of desired compound **21** at higher temperature (> 70°C) likely through competing β -elimination pathways. After removing excess HCl, the obtained amino acid was directly protected with benzyl chloroformate for easier isolation producing racemic Cbz-3,3-difluoroproline derivate **22** in 81% yield over three steps from **20**.

This synthetic pathway was useful to prepare several grams of 3,3-difluoroproline, but for larger batches, we used Moyer et al.'s²⁶ synthesis of cyclic α -amino- β -keto ester **27**

(Scheme 4), but modified the protecting groups to simplify the chemistry. The *tert*-butyl ester could be cleaved at room temperature, leaving the Cbz-group needed for the resolution step. The key step of the synthetic pathway is the cyclization of α -diazo- β -keto ester in presence of $\text{Rh}_2(\text{OAc})_4$.

β -keto ester **25** was obtained by a Masamune-Claisen condensation between the two commercially available carboxylic acids **23** and **24** in presence of 1,1'-carbonyldiimidazole (CDI) and isopropylmagnesium bromide. The diazo group was introduced by diazo transfer from the 3-carboxybenzenesulfonyl azide²⁷ in 95% yield. The resulting *m*-carboxybenzenesulfonamide can be easily removed from desired compound **26** by an alkaline wash. Cyclization of the α -diazo β -keto ester **26** in the presence of $\text{Rh}_2(\text{OAc})_4$ gave **27** in 91% yield. Deoxofluorination was performed in the presence of DAST to afford the β,β -difluoroproline derivate **28** in 71% yield. Prior to the fluorination step, no silica gel chromatography was needed which was advantageous on multi-gram scale (> 30 g). Moreover, the presence of the Cbz protecting group from the beginning of the synthesis facilitated reaction monitoring by UV and was desired for the resolution step. Another advantage of this synthetic pathway was the presence of the *t*-butyl ester which was cleaved under milder conditions than the ethyl ester. The use of TFA/DCM at rt, during the hydrolysis instead of 6N HCl at 60°C reduced the risk of formation of undesired side products.

We next tackled the resolution of our racemic material. Tyrosine hydrazide (Tyr-NHNH_2) has been shown to efficiently resolve several amino acid derivatives.^{28–30} Vogler and Lanz²⁸ reported that L-tyrosine hydrazide could resolve DL-amino acids to provide the D-antipodes with high efficiency and enantiomeric excess. Fortunately, in this case, the 3,3-bis-fluorine substitution did not interfere with the resolution, and using D-tyrosine hydrazide, we isolated the salt of acid **29** after filtration, with 99%ee and 80% yield after the first crystallization (Scheme 5). D-tyrosine hydrazide was easily prepared from D-tyrosine (\$0.50/gram) in two steps (93% yield on 3 kg scale) following the same method as described for the L-tyrosine hydrazide after recrystallization.³¹ An acidic wash removed the hydrazide, which could be recovered and recycled.²⁸ A second crystallization of the mother liquor with L-tyrosine hydrazide afforded the opposite enantiomer, (S)-3,3-difluoro-Cbz-proline **30** with 99%ee and 80% yield following acidic work-up. The same yield and enantiomeric excess were observed during the resolution of acid **22** on milligram scale (20 mg) as well as on 70 g scale. Enantiomeric excess was determined using chiral HPLC (see supporting information). The deprotection of the Cbz group by hydrogenation (99% yield) afforded enantiopure 3,3-difluoroproline in 5 steps from commercially available starting materials.

In summary, the synthetic pathway described herein gives access to optically pure (S)- and (R)-3,3-difluoroproline with good yields at each step. Purification by flash chromatography was only necessary after the key fluorination step, allowing for the easy production of gram quantities of the desired compound. 3,3-difluoroproline could be used as a scaffold in medicinal chemistry or in non-natural peptide synthesis.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Supported by the National Institute on Drug Abuse (DA033622 to T.M.K.).

References

1. Swallow S. *Prog. Med. Chem.* 2015; 54(2):65–133. [PubMed: 25727703]
2. Purser S, Moore PR, Swallow S, Gouverneur V. *Chem. Soc. Rev.* 2008; 37(2):267–432.
3. Hagmann WK. *J. Med. Chem.* 2008; 51(15):4359–4369. [PubMed: 18570365]
4. Müller K, Faeh C, Diederich F. *Science.* 2007; 317(317):1881–1886. [PubMed: 17901324]
5. Gillis EP, Eastman KJ, Hill MD, Donnelly DJ, Meanwell NA. *J. Med. Chem.* 2015; 58(21):8315–8359. [PubMed: 26200936]
6. Hodgest JA, Raines RT. *J. Am. Chem. Soc.* 2003; 125(31):9262–9263. [PubMed: 12889933]
7. Jäckel C, Salwiczek M, Kokscho B. *Angew. Chemie - Int. Ed.* 2006; 45(25):4198–4203.
8. Cornilescu G, Hadley EB, Woll MG, Markley JL, Gellman SH, Cornilescu CC. *Protein Sci.* 2007; 16(9):14–19. [PubMed: 17123960]
9. Marsh ENG. *Acc. Chem. Res.* 2014; 47(10):2878–2886. [PubMed: 24883933]
10. Qiu Z, Lin X, Zhou M, Liu Y, Zhu W, Chen W, Zhang W, Guo L, Liu H, Wu G, Huang M, Jiang M, Xu Z, Zhou Z, Qin N, Ren S, Qiu H, Zhong S, Zhang Y, Zhang Y, Wu X, Shi L, Shen F, Mao Y, Zhou X, Yang W, Zhen Wu J, Yang G, Mayweg AV, Shen HC, Tang G. *J. Med. Chem.* 2016; 59(16):7651–7666. [PubMed: 27458651]
11. Jansen K, Heirbaut L, Verkerk R, Cheng JD, Joossens J, Cos P, Maes L, Lambeir A, De Meester I, Augustyns K, Van Der Veken P. *J. Med. Chem.* 2014; 57(7):3053–3074. [PubMed: 24617858]
12. Gardelli C, Nizi E, Muraglia E, Crescenzi B, Ferrara M, Orvieto F, Pace P, Pescatore G, Poma M, Ferreira MDRR, Scarpelli R, Homnick CF, Ikemoto N, Alfieri A, Verdirame M, Bonelli F, Paz OG, Taliani M, Monteagudo E, Pesci S, Laufer R, Felock P, Stillmock KA, Hazuda D, Rowley M, Summa V. *J. Med. Chem.* 2007; 50(20):4953–4975. [PubMed: 17824681]
13. De Bruin G, Huber EM, Xin BT, Van Rooden EJ, Al-Ayed K, Kim KB, Kisselev AF, Driessen C, Van Der Stelt M, Van Der Marel GA, Groll M, Overkleeft HS. *J. Med. Chem.* 2014; 57(14):6197–6209. [PubMed: 25006746]
14. Hart BP, Coward JK. *Tetrahedron Lett.* 1993; 34(31):4917–4920.
15. Tamaru Y, Kawamura S, Bando T, Tanaka K, Yoshida Z. *J. Org. Chem.* 1988; 53(2):5491–5501.
16. Shi G-Q, Cai W-L. *J. Org. Chem.* 1995; 60(20):6289–6295.
17. Suzuki A, Mae M, Amii H, Uneyama K. *J. Org. Chem.* 2004; 69(15):5132–5134. [PubMed: 15255751]
18. Kirk KL. *Org. Process Res. Dev.* 2008; 12(2):305–321.
19. Bildstein S, Ducep J-B, Jacobi D, Zimmermann P. *Tetrahedron Lett.* 1995; 36(28):5007–5010.
20. Li W, Oliver E, Rojas C, Kalish V, Belyakov S. WO 2004/071454.
21. Burnett D, Bursavich MG, Mcriner A. WO 2015/109109.
22. Kamenecka TM, He Y. WO 2016/025669.
23. Lal GS, Pez GP, Pesaresi RJ, Prozonic FM, Cheng H. *J. Org. Chem.* 1999; 64(19):7048–7054.
24. Hudlicky M. *Org. React.* 1988; 35:513–637.
25. L'heureux A, Beaulieu F, Bennett C, Bill DR, Clayton S, Laflamme F, Mirmehrabi M, Tadayon S, Tovell D, Couturier M. *J. Org. Chem.* 2010; 75(10):3401–3411. [PubMed: 20405933]
26. Moyer MP, Feldman PL, Rapoport H. *J. Org. Chem.* 1985; 50(12):5223–5230.
27. Moreau RJ, Sorensen EJ. *Tetrahedron.* 2007; 63(28):6446–6453.
28. Vogler K, Lanz P. *Helv. Chim. Acta.* 1966; 49(4):1348–1354.

29. Rodebaugh RM, Cromwell NH. J. Heterocycl. Chem. 1969; 6(6):993–994.
30. Jaen, JC. e-Eros Encycl. Reagents Org. Synth. John Wiley Sons, LTd, Ed.; Chichester, UK: 2011.
31. Kudelko A, Zielinski W, Ejsmont K. Tetrahedron. 2011; 67(40):7838–7845.

Highlights

- Enantioselective synthesis of 3,3-difluoroproline
- Short scalable synthesis
- Resolution provided both enantiomer in high ee and yield

Scheme 1.

Synthesis of DL-3,3-difluoroproline derivative from masked 3-hydroxyprolinol **3**.^a

^aReagents: a) $(\text{CF}_3\text{CO})_2\text{O}$, DMSO, Et_3N , CH_2Cl_2 , 73%; b) DAST, CH_2Cl_2 , -78°C to rt, 64%; c) 6N HCl, reflux; d) $(\text{Boc})_2\text{O}$, NaHCO_3 , CHCl_3 , H_2O , 92% from **5**; e) $\text{RuO}_2 \cdot x\text{H}_2\text{O}$, 10% NaIO_4 , EtOAc; f) CH_2N_2 , Et_2O , 93% from **6**.

Scheme 2. Initial synthesis of enantiopure 3,3-difluoroproline derivative.^a

^aReagents: a) Mg, NaI, Me₃SiCl, DMF, 50%; b) NBS, CH₂Cl₂, rt, 97%; c) H₂, Pd(OCOCF₃)₂, (R)-BINAP, rt; d) allyltributyltin, AIBN, toluene, 90°C, 87% from **10**; e) CHTD, BnOH, toluene, reflux, 89%; f) *i*CAN, CH₃CN, 0°C, *ii* Na₂S₂O₃, CBzCl, NaHCO₃, 0°C, 39%; g) *i* O₃/O₂, CH₂Cl₂, -78°C, *ii* Me₂S, -78°C to rt, 77%; h) PPh₃.Cl₂, DMF, 0°C to rt; i) H₂ (1 atm), RhCl(PPh₃)₃, benzene, rt, 87%, > 99% ee.

Scheme 3. Difluorination of N-Boc-3-oxopyrrolidine-2-carboxylate.^a^aReagents: a) DAST, neat, 0°C-rt, 18h, 64%; b) HCl 6N, 60°C, 5h; c) CbzCl, NaHCO₃, H₂O, THF, rt, 24h, 81% over two steps.

Scheme 4.

Preparation and fluorination of N-Cbz-3-oxopyrrolidine-2-carboxylate.^a

^aReagents: a) (i) CDI, THF, rt, 18h; (ii) *i*PrMgBr, 0°C-rt, 5h, 95%; b) m-carboxybenzenesulfonyl azide, CH_3CN , Et_3N , rt, 2h, 95%; c) $\text{Rh}_2(\text{OAc})_4$, toluene, 90°C, 1h, 91%; d) DAST, DCM, rt, 18h, 71%; e) TFA, DCM, rt, 5h, qt.

Scheme 5. Chiral resolution ^a

^aReagents: a) (i) D-tyrosine hydrazide, iPrOH, MeOH, 90°C-rt, 18h; (ii) HCl 1N, 80%, 99%ee; b) L-tyrosine hydrazide, iPrOH, MeOH, 90°C-rt, 18h; (ii) HCl 1N, 80%, 99%ee; c) Pd/C, H₂, EtOAc, rt, 18h, 99%.